Fibrogen_US_Primary_logo_RGB_M01.jpg
The New England Journal of Medicine (NEJM) Publishes Roxadustat China Phase 3 Results for the Treatment of Anemia in Chronic Kidney Disease Patients Receiving Dialysis
24 juil. 2019 18h53 HE | FibroGen, Inc
-- One of Two Concurrent Publications of Roxadustat China Phase 3 Results in The New England Journal of Medicine -- SAN FRANCISCO, July 24, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN)...
Fibrogen_US_Primary_logo_RGB_M01.jpg
FibroGen Reports Third Quarter 2018 Financial Results
08 nov. 2018 16h02 HE | FibroGen, Inc
—Roxadustat New Drug Applications under Review in China and Japan——Phase 3 Clinical Trials in IPF and Pancreatic Cancer to Initiate in First Quarter 2019——Conference Call Today at 5:00 p.m. Eastern...
Fibrogen_US_Primary_logo_RGB_M01.jpg
FibroGen Announces Four Clinical Presentations on Roxadustat at Upcoming American Society of Nephrology Kidney Week 2018 Annual Meeting
16 oct. 2018 16h27 HE | FibroGen, Inc
Roxadustat Phase 3 Clinical Results in Late-Breaking Clinical Trial Posters and Oral Presentation   SAN FRANCISCO, Oct. 16, 2018 (GLOBE NEWSWIRE) --  FibroGen, Inc. (NASDAQ: FGEN), a leading...
Fibrogen_US_Primary_logo_RGB_M01.jpg
Astellas Submits New Drug Application in Japan of Roxadustat for The Treatment of Anemia Associated with Chronic Kidney Disease in Patients on Dialysis
01 oct. 2018 08h00 HE | FibroGen, Inc; Astellas Pharma Inc.
TOKYO and SAN FRANCISCO, Oct. 01, 2018 (GLOBE NEWSWIRE) -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and FibroGen, Inc. (Nasdaq: FGEN, CEO: Thomas B....
FibroGen Reports Fir
FibroGen Reports First Quarter 2018 Financial Results
09 mai 2018 16h02 HE | FibroGen, Inc
Pamrevlumab Data to be Presented at ATS 2018 and ASCO 2018 Roxadustat U.S. Phase 3 Clinical Studies on Track to Readout in Fourth Quarter 2018Conference Call Today at 5:00 p.m. Eastern Time/2:00...
Fibrogen_US_Primary_logo_RGB_M01.jpg
FibroGen Announces Acceptance by China FDA of Roxadustat New Drug Application (NDA) for Treatment of Anemia Associated With Dialysis and Non-Dialysis Chronic Kidney Disease (CKD)
18 oct. 2017 07h00 HE | FibroGen, Inc
SAN FRANCISCO, Oct. 18, 2017 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a science-based biopharmaceutical company, and its subsidiary FibroGen China Medical Technology Development Co., Ltd....
Fibrogen_US_Primary_logo_RGB_M01.jpg
European Patent Office Maintains FibroGen Patent Relating to Hypoxia-Inducible Factor (HIF) Prolyl Hydroxylase Inhibitor Technology
05 juin 2017 07h00 HE | FibroGen, Inc.
SAN FRANCISCO, June 05, 2017 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a science-based biopharmaceutical company, announced today that a FibroGen European patent relating to the therapeutic...
Fibrogen_US_Primary_logo_RGB_M01.jpg
Positive Results Published in Nephrology Dialysis Transplantation From Two China Phase 2 Trials of Roxadustat for Treatment of Anemia in Chronic Kidney Disease
30 mars 2017 07h00 HE | FibroGen, Inc.
SAN FRANCISCO, March 30, 2017 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a science-based biopharmaceutical company, today announced that clinical results from two Phase 2 studies in China of...
Fibrogen_US_Primary_logo_RGB_M01.jpg
FibroGen’s Roxadustat (FG-4592) Meets Primary Endpoints in Two Phase 3 Anemia Studies in China
30 janv. 2017 07h00 HE | FibroGen, Inc.
SAN FRANCISCO, Jan. 30, 2017 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a science-based biopharmaceutical company, and its subsidiary FibroGen China Medical Technology Development Co., Ltd....
Fibrogen_US_Primary_logo_RGB_M01.jpg
FibroGen Reports Financial Results for the Second Quarter of 2016
08 août 2016 16h02 HE | FibroGen, Inc.
Enrollment Completed in Placebo-Controlled Study of FG-3019 (Pamrevlumab) in IPF China Phase 3 Top Line Data Expected by Year-End 2016 –Webcast Conference Call Scheduled for 4:30pm EDT Today– ...